Drug Profile
Research programme: neuroinflammatory disorders therapeutics - Vasogen
Alternative Names: VP series drug programme; VP-015Latest Information Update: 30 Oct 2009
Price :
$50
*
At a glance
- Originator Vasogen
- Developer Intellipharmaceutics International
- Class Phospholipids
- Mechanism of Action Cytokine modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Alzheimer's disease; Neurological disorders; Parkinson's disease
Most Recent Events
- 22 Oct 2009 Vasogen has merged with IntelliPharmaCeutics Corp to form Intellipharmaceutics International
- 09 Jul 2008 Suspended - Preclinical for Alzheimer's disease in Canada (unspecified route)
- 09 Jul 2008 Suspended - Preclinical for Neurological disorders in Canada (unspecified route)